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An international expert panel, active within
theEuropeanSocietyforBloodandMarrow
Transplantation, European LeukemiaNet,
Blood andMarrow Transplant Clinical Trial
Group, and the International Myelodys-
plastic Syndromes Foundation developed
recommendations for allogeneic hemato-
poietic stem cell transplantation (HSCT) in
myelodysplastic syndromes (MDS) and
chronicmyelomonocytic leukemia (CMML).
Disease risks scored according to the
revised International Prognostic Scoring
System (IPSS-R) and presence of comor-
bidity graded according to theHCTComor-




features, profound cytopenias, and high
transfusionburdenarecandidates forHSCT.
Patients with a very high MDS transplanta-
tion risk score, based on combination of
advanced age, high HCT-CI, very poor-risk
cytogeneticandmolecular features,andhigh
IPSS-R score have a low chance of curewith
standard HSCT and consideration should
be given to treating these patients in in-
vestigational studies. Cytoreductive therapy
prior to HSCT is advised for patients with
‡10% bone marrow myeloblasts. Evidence
from prospective randomized clinical trials
doesnot provide support for specific recom-
mendations on the optimal high intensity
conditioning regimen. For patientswith con-
traindications to high-intensity preparative
regimens, reduced intensity conditioning
should be considered. Optimal timing of HSCT
requires careful evaluation of the available
effective nontransplant strategies. Prophylac-
tic donor lymphocyte infusion (DLI) strate-
gies are recommended in patients at high risk
of relapse after HSCT. Immune modulation
by DLI strategies or second HSCT is advised
if relapse occurs beyond 6 months after
HSCT. (Blood. 2017;129(13):1753-1762)
Introduction
Despite improved understanding of the molecular pathogenesis of
myelodysplastic syndromes (MDS), currently available therapeutic
agents lead to prolongation of life and no cure.1 Therefore, allogeneic
hematopoietic stem cell transplantation (HSCT) is increasingly used as
a curative treatment option.2 This increase in HSCT activity can
be attributed largely to the introduction of reduced-intensity (RI)
regimens that have extended the indication for HSCT to patients with
comorbidities or reducedﬁtness. The ever increasing use of unrelatedor
mismatched familydonors also contributes to the frequent use ofHSCT
inMDS.3 Several factors have to be considered in the decision process
of “how to select MDS patients as suitable candidates for HSCT.”
These can be classiﬁed into patient-related and disease-related factors.
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These factorsmay determine response to treatmentmodalities, including
intensive chemotherapy (ICT),4 hypomethylating agents (HMAs),
immunomodulatory agents, such as lenalidomide,5 and hematopoi-
etic growth factors.6
The Chronic Malignancies Working Party (CMWP) of the
European Blood and Marrow Transplant Society (EBMT) has
developed an initiative to reﬁne and update the general international
guidelines7,8 for patients with MDS who are potential candidates for
HSCT. Using the information from the general MDS guidelines,7,8 an
expert task force developed HSCT scenarios for patients with MDS,
which were evaluated and discussed by a panel of experts during
several consensus meetings. This international expert panel, consisting
of members of the European Society for Blood and Marrow
Transplantation, European LeukemiaNet, the Blood and Marrow
Transplant Clinical Trial Group, and the International Myelodys-
plastic Syndromes Foundation, developed the recommendations
presented in this article.
Design and methods
The task force has followed the procedures used for the development of the
current European Leukemia Net (ELN) MDS guidelines.7 Consensus develop-
ment for the recommendations of the guidelines was based on a systematic
literature review and scenario analysis by 32 transplant and nontransplant MDS
experts fromEurope and theUnitedStates.Theﬁrst roundof scenarioswasbased
on the issues raised in the general ELNMDS guidelines; the second round was
based on the outcome of expert suggestions raised during the consensus
meetings. The scenarioswere considered to have yielded a consensuswhenmore
than two-thirds of the experts agreed and the remaining experts accepted the
proposed scenario. The level of evidence was rated according to the Revised
Grading System for Recommendations in Evidence Based Guidelines of the
Scottish Intercollegiate Guidelines Network Grading Review Group
(supplemental Data Section 1, see supplemental Data available at the Blood
Web site).9 Patients in certain scenarios might have a dismal outcome either
with or without HSCT. These patients might be recommended for HSCT in
clinical trials.
General structure of the recommendations
The expert panel assumed that the diagnostic approaches and the nontransplant
strategies in individual patients followed the recommendations of the general
diagnosticguidelines.7,8Theexpert panel agreed toavoid topicsdealingwithgeneral
issues aroundHSCT, pertaining to all indications includingMDS.We analyzed the
impact of the individual components of the current risk-scoring systems because
these variables might have different impact on outcomes after ICT, HMA, and
HSCT (summarized in Table 1). Several HSCT approaches are available: HSCT
immediately after diagnosis or delayed transplantationafter progressionof diseaseor
after failure of nontransplant strategies. HSCTmay be performedwithout reduction
of disease burden prior to conditioning or after cytoreduction. The general
transplantation risk index deﬁned by Armand et al10 and the EBMT transplantation
risk score,11 might not be sufﬁciently speciﬁc for MDS because speciﬁc risk
categories, including percentage of marrow blasts, cytogenetic risk groups, and
severity of cytopenias are lacking. The ELN and the National Comprehensive
Cancer Network (NCCN) formulated the general recommendation for HSCT at
diagnosis based on the International Prognostic Scoring System (IPSS).7,8 The
panel recognized the disease risk scored according to the revised IPSS (IPSS-R)
and Comorbidity Index (CI), graded according to the Hematopoietic Cell
Table 1. Prognostic risk factors relevant for HSCT eligibility and for outcome after HSCT
Prognostic risk factor




including supportive care HSCT
Patient related
Age (chronological) Calendar, IPSS-R20 Age influences prognostic impact of
disease-related factors20
Impact age influenced by other patient-
related factors15
Performance status (functional ability) Karnofsky status $ 80% Better survival after HSCT15
Frailty (reduced physical fitness) Specific tools have to be tested in
HSCT117
Fit patients better outcome12,16-18
Comorbidities HSCT-specific CI (HCT-CI)14 Low CI better outcome13
Disease related
Percentage of marrow blasts IPSS(-R), WPSS, WHO20,21 Related to prognosis20,21 Only impact if ,5% marrow blasts22
Cytogenetic risk groups IPSS(-R), WPSS, CPSS20,21,44 5 prognostic groups19 Only very-poor-risk29 and monosomal
karyotype30
Severity of cytopenias IPSS(-R), WPSS41,42 IPSS-R better prediction of prognosis
compared with IPSS42
Only very-poor-risk group of IPSS-R
prognostic
Marrow fibrosis WHO criteria51 Severity fibrosis prognostic51 Severity fibrosis prognostic52
Transfusions burden WPSS41,63 WPSS41 WPSS64
FCM ELN FCM score25,27 ELN FCM score24 Not validated yet27
Molecular mutations No specific tools yet34 Mutations in RUNX1, U2AF1, ASXL1,
TP53, and others: poor prognosis34
Mutations in TP53, EZH2, ETV6 poor
prognostic23,35
Disease status (after nontransplant
treatment interventions)
ESA failure High Epo levels, high transfusion
intensity6,68
High Epo levels, high transfusion
intensity6,68
No direct impact reported
Lenalidomide failure Absence of 5q25 Absence of 5q25 No direct impact reported
HMA failure HMA-therapy–specific risk score71 HMA-therapy–specific risk score,71
complex karyotype118 TET2 and TP53
mutations72,73
Best available treatment after HMA
failure,76 but response status
prognostic factor
ICT MDS-specific risk score4 MDS-specific risk score4 Best available treatment available after
failure of first-line ICT,70 but response
status and remission duration
prognostic factor31
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Transplantation–Comorbidity Index (HCT-CI), as the most relevant clinical
variables for patients for HSCT eligibility. In the following sections, we will
discuss factors that need to be considered for HSCT recommendations.
Specific recommendations
Risk factors
Patient characteristics. Age,12 performance status (functional ability),
frailty (reduced physical ﬁtness or physical reserve), and comorbidities13
are important patient-related factors which determine outcome after
HSCT. Prognostic tools, including performance status (eg, Karnofsky
score) and HSCT-speciﬁc CI (HSCT-CI),14 show a strong prognostic
impact on outcome, independently of disease characteristics. The
impact of age per se is less evident, if other factors, including HSCT-CI
are considered appropriately.15A recent study16 showed that higher-risk
patients, aged 60 to 70 years, beneﬁt from transplantation after RI
regimens.Allﬁt patientswithout comorbidities shouldbe considered for
HSCT, provided that disease-related factors allow the recommendation
for HSCT (Figures 1 and 2)12,16-18 (recommendation level C). Nonﬁt
higher-risk MDS patients with multiple comorbidities and/or reduced
performance status are generally not candidates for HSCT, but these
patientsmay be considered forHSCT in clinical trials (recommendation
level D).
Disease-related factors. The IPSS-R is an age-adjusted risk
score and is based on 3 parameters: percentage of marrow blasts,
modiﬁed cytogenetic risk groups,19 and the severity of cytopenias.20
The IPSS-R can be simpliﬁed into 3 risk groups when considering
HSCTas a treatment option: lower risk (lowandvery-low IPSS-R risk),
intermediate risk, and higher risk (high and very-high IPSS-R risk).
Percentage of BM myeloblasts and ﬂow cytometric characteristics.
The percentage of bone marrow (BM)myeloblasts is incorporated into
all current prognostic scoring systems in MDS.20,21 However, the
overall survival of MDS patients, primarily treated with HSCT, is not
signiﬁcantly inﬂuenced by the percentage of myeloblasts, except for
patients with ,5% myeloblasts who showed a better outcome.22 No
consensus was reached as to whether intermediate-risk patients with
myeloblasts between 5% and 10% should be considered for HSCT
immediately after diagnosis or after development of additional risk
factors.23 General consensus was obtained concerning the indication
for HSCT early after diagnosis in ﬁt, higher-risk patients if myeloblasts
exceed 10% (recommendation level C).
Flow cytometry (FCM) may be used in addition to general risk
assessment, choice of therapy, and monitoring of disease activity in
adult patients withMDS.24,25 The severity of pretransplantation ﬂow
cytometric aberrancies on marrow cells correlated with posttrans-
plantation relapse in 1 study.26 Widespread clinical implementa-
tion of FCM is still lacking, despite published standardization
protocols.27
Cytogenetic characteristics. The new cytogenetic risk classi-
ﬁcation19,28 has prognostic signiﬁcance following HSCT. The very-
poor-risk category predicts for increased mortality and relapse
following HSCT.29 The presence of complex karyotype abnormalities,
monosomal karyotype or both predicted inferior survival afterHSCT in
MDS patients.30 A recent study in 903 MDS patients showed poor
survival in the IPSS-R cytogenetic poor-risk group in combinationwith
monosomal karyotype.31 The cytogenetic classiﬁcation in IPSS-R has
changed the prognostic impact of some cytogenetic subcategories. For
example, del (7q) as a single abnormality is classiﬁed as intermediate
cytogenetic risk,which implies that such a patientmay qualify as a low-
riskpatient.No consensuswas reached as towhether this patient should
be proposed for HSCT immediately after diagnosis.
Molecular characteristics. Molecular characteristics signiﬁ-
cantly impact on the prognosis of MDS.23,32,33 MDS associated with
SF3B1 mutations34 form a distinct entity with a favorable prognosis.
DNMT3A, TET2, IDH1, and IDH2 are associated with multilineage
dysplasia.34 SRSF2, RUNX1, U2AF1, ASXL1, and TP53 mutations
are associated with poor prognosis.34 Bejar et al23 reported prognostic
signiﬁcance for EZH2 and ETV6 mutations in a study of 87 allograft
recipients.35 TP53 mutations and especially the combination of





















Figure 1. Therapeutic algorithm for adult patients
with MDS and (very) low-risk or intermediate IPSS-
R risk scores. @ indicates nonfit (patients with multiple
comorbidities and/or poor performance) or fit (patients
with no comorbidities and good performance status).
* indicates nontransplant strategies according to most
recent versions published by international MDS expert
groups, including ELN and NCCN. & indicates failure of
nontransplant strategies (for details of various non-
transplant interventions [transfusions, ESAs, lenalido-
mide, and cytoreductive therapy], see “Timing of
transplantation.” Nontransplant interventions may in-
clude .1 line of nontransplant intervention, eg,
treatment with ESAs, followed by lenalidomide in
patients with 5q2). ** indicates poor-risk features
(defined as poor-risk cytogenetic characteristics, per-
sistent blast increase [.50% or with .15% BM blasts],
life-threatening cytopenias [neutrophil counts, ,0.3 3
109/L; platelet counts, ,30 3 109/L], high transfusion
intensity $2 units per months for 6 months; molecular
testing should be seriously considered, in case of
absence of poor-risk cytogenetic characteristics or
persistent blast increase). # indicates transplant strat-
egies (all forms of HSCT, for details of donor selection,
type of conditioning and posttransplant strategies, see
text; no upper age limit if patients are fit, without serious
comorbidity and good Karnofsky status). @ indicates
donor availability (the improved outcome of HSCT with
haploidentical donors utilizing posttransplant cyclo-
phosphamide increases the donor availability).
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after HSCT.35 A recent study in 401 patients who received HSCT for
MDS or MDS/acute myeloid leukemia (AML) showed that somatic
mutations in ASXL1, RUNX1, or TP53 were independently associated
with unfavorableoutcomes and shorter survival after allogeneicHSCTfor
patients with MDS and MDS/AML.36 A high prevalence of SRSF2
mutations has been reported in patients with chronic myelomonocytic
leukemia (CMML)with concurrent TET2 or ZRSR2mutations, but only
ASXL1 mutations retained their prognostic signiﬁcance in a multivariate
prognostic score.37,38 A large Center for International Blood andMarrow
TransplantResearch (CIBMTR) study (in total 1514patients) presented at
the 2016 American Society of Hematology (ASH) annual meeting
reported relevant new ﬁndings. RAS pathway mutations and JAK2
mutations were associated with a poor outcome after allogeneic HSCT,
independently of TP53mutations in patients older than 40 years.39 HSCT
in clinical trials may be considered for patients with ASXL1, RUNX1,
RAS pathway and JAK2, and especially TP53 mutations. The relatively
poor survival afterHSCTsuggests that new transplantation strategiesmust
be developed for these patients, including posttransplant strategies to
prevent relapse (Recommendation level D).
Cytopenias, including RBC transfusion dependence. The
presence and the degree of cytopenias contribute to the IPSS-R
classiﬁcation riskscore.20 Symptomatic, severe cytopenias refractory to
growth factors or requiring intensive red blood cell (RBC) transfu-
sion support may be independent indications for HSCT. Usually,
this indication requires observation time (see “Timing of
transplantation”).
WHO classiﬁcation, WPSS, IPSS, and IPSS-R. The World
HealthOrganization (WHO) classiﬁcation has been updated recently,40
but its contribution to the outcome in relation to HSCT recommenda-
tions has not been evaluated yet. The WHO classiﬁcation-based
prognostic system (WPSS) uses a previous version of the WHO
classiﬁcation.41 A recent study showed that IPSS-R provided better
prediction of survival after HSCT compared with IPSS.42 The IPSS-R
changed the risk groups in about 65% of patients.42 Patients with a
very-high-risk score (.4points) basedonage,CI,monosomalkaryotype,
and IPSS-R42 appear to have a low cure rate by HSCT and should
be considered for investigational studies (recommendation level C).
Other subtypes of MDS
Chronic myelomonocytic leukemia. The 2008WHOclassiﬁcation
distinguishes 2 different types of CMML based on percentage of blasts
and promonocytes in peripheral blood (PB) and BM.43 The panel
agreed to use the CMML-speciﬁc scoring system (CPSS)44 for the
recommendationofHSCT forCMMLpatients, but IPSS-Rmayalsobe
used for patientswith the dysplastic type ofCMML.Froma recent large
retrospective analysis on 513 CMML patients, treated with HSCT, it
appears that achievement of a better remission state before HSCT is the
most important prognostic factor for a favorable outcome.45 The
experts agreed to recommend upfront HSCT in cases of CPSS
intermediate-2 or high risk (recommendation level D). Many experts
would consider pretreatment with HMA in cases of CMML-2 and an
indication for HSCT, preferably early after diagnosis, but evidence
from prospective clinical trials and retrospective analyses is lacking.
Treatment-related MDS. The prognosis of treatment-related
MDS (t-MDS) is generally worse compared with de novoMDS.46 The
CIBMTR analyzed a series of 323 t-MDS patients treated with
HSCT.47Age.35years, poor-risk cytogenetics, advanced t-MDS, and
alternative donors were negative prognostic factors for post-HSCT
outcome. The major cause of failure after HSCT was nonrelapse
mortality (NRM).48 The 5-year relapse-free survival in this group of
257 patients with t-MDS/transformed AML was 29%. Multivariate
analyses failed to show signiﬁcant differences in outcome, when the
t-MDScohortwas comparedwitha cohort of 339patientswho received
HSCT for de novo MDS/transformed AML.49 Overall survival rates
improved signiﬁcantly (P , .001) per calendar year in a large cohort
(461 patients) due to a marked reduction in NRM.50 The expert panel























Figure 2. Therapeutic algorithm for adult patients
with MDS and poor IPSS-R scores. @ indicates nonfit
(patients with multiple comorbidities and/or poor perfor-
mance) or fit (patients with no comorbidities and good
performance status). * indicates nontransplant strategies
according to most recent versions published by in-
ternational MDS expert groups, including ELN and
NCCN. & indicates failure of nontransplant strategies
(for details of various nontransplant interventions [trans-
fusions, ESAs, lenalidomide and cytoreductive therapy],
see “Timing of transplantation.” Nontransplant interven-
tions may include .1 line of nontransplant intervention,
eg, treatment with ESAs, followed by lenalidomide in
patients with 5q2). ** indicates poor-risk features
(defined as poor-risk cytogenetic characteristics, persis-
tent blast increase [.50% or with .15% BM blasts], life-
threatening cytopenias [neutrophil counts,,0.33 109/L;
platelet counts, ,30 3 109/L], high transfusion
intensity $2 units per months for 6 months; molecular
testing should be seriously considered, in case of absence
of poor-risk cytogenetic characteristics or persistent blast
increase). # indicates transplant strategies (all forms of
HSCT, for details of donor selection, type of conditioning
and posttransplant strategies, see text; no upper age limit
if patients are fit, without serious comorbidity and good
Karnofsky status). @ indicates donor availability (the im-
proved outcome of HSCT with haploidentical donors
utilizing posttransplant cyclophosphamide increases the
donor availability).
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follow the recommendations developed for de novoMDS/transformed
AML (recommendation level D).
MDS with BM ﬁbrosis. MDS patients with marrow ﬁbrosis
usually have pancytopenia. The IPSS-R classiﬁcation can be used to
assess prognosis, but the severity of BM ﬁbrosis should also be
considered.51 The outcome ofHSCTwas analyzed among 721 patients
withknownBMhistologyat timeofHSCT.52Thedegreeofﬁbrosis did
not correlate with disease status nor abnormal cytogenetics. The 3-year
survival in this studywas 49%, 40%, and 21% in patientswith no,mild/
moderate, or severeBMﬁbrosis, respectively.52PatientswithMDSand
marrowﬁbrosis should be considered forHSCTbefore development of
severe marrow ﬁbrosis (recommendation level D).
Hypoplastic MDS. HypoplasticMDS has distinct features when
comparedwith otherMDS typeswith low blast inﬁltration in themarrow,
but the distinction between severe aplastic anemia and severe hypoplastic
MDS might be difﬁcult, especially in the absence of speciﬁc cytogenetic
abnormalities or molecular genetic markers.53 In general, the IPSS risk
scoredoespredict survivalwell inhypoplasticMDSpatients.54Aminority
of patients with hypoplasticMDSmay respond to immunosuppression.55
The timingofHSCTdependson the severityof cytopenias, the intensityof
RBC transfusions, and the probability of response to immunosuppression
(for details, see “Timing of transplantation”).
MDS originating from inherited germ line mutations. These
forms of MDS should be considered in young patients (,40-50 years)
with a (family) history of dyskeratosis congenita, Fanconi anemia (FA),
Shwachman-Diamond Syndrome, Diamond-Blackfan anemia,56 and
GATA2 mutations.57,58 Speciﬁc germ line mutations and mutations in
the genes of the telomerase complex may occur more frequently in
these disorders.56,57 These patients may be candidates for HSCT at an
early stage and should be referred to specialist centers in view of the
speciﬁc sensitivity to conditioning in someof these syndromes (eg, FA)
and the selectionof familydonorswhomay carry the involvedmutation
(recommendation level C).
MDS with multilineage dysplasia deﬁned by WHO2008.
Refractory cytopeniawithmultilineagedysplasia (RCMD) is anaccepted
subtype according to the 2008 WHO classiﬁcation.43 The prognosis of
patients with RCMD is similar to the prognosis of other MDS patients
with ,5% marrow blasts, bearing in mind the prognostic impact of
individual cytogenetic59 and molecular characteristics.34 The expert
panel agreed that the recommendations for HSCT in RCMD should
follow the recommendations for MDS without MD, taking into account
the established risk factors, including genetic risk factors (recommenda-
tion level D).
Donor selection
Potential stem cell donors include standard donors, such as HLA-
matched siblings, syngeneic donors and matched (8 of 8) unrelated
donors, and alternative stem cell donors, including umbilical cord
blood donors. Selection of stem cell donors for patients with MDS
has improved markedly during the last 2 decades similar to other
indications for HSCT (supplemental Data Section 2). The expert panel
agreed to accept as standard donors: HLA-identical siblings (including
1 class I[A/B] mismatch), syngeneic donors and 8 of 8 (or 10 of 10)
matched unrelated donors (MUDs; recommendation level D). In
addition, the expert panel recommends considering age, sex, and
cytomegalovirus (CMV) status of donors during the donor selection
process and to follow the recently formulated donor suitability criteria
(recommendation level C; supplemental Data Section 2).60
Alternative donor transplantsmay be considered for higher-risk and
ﬁt patients, for whom no matched sibling donor or MUD can be
identiﬁedwithin a reasonable search period (recommendation level D).
Factors of relevance for selection of the source of
hematopoietic cells
The role of hematopoietic cell sources in HSCT for MDS has been
investigated in retrospective studies,61,62 similar to other indications for
HSCT (supplemental Data Section 3). The source of hematopoietic
cells should not inﬂuence the preferred preparation for MDS patients
with an accepted indication for HSCT (recommendation level C).
Timing of transplantation
Poor-risk factors incorporated in prognostic scores. Usually,
lower-risk patients at diagnosis according to IPSS-R remain lower risk
over time, whereas the prognosis in higher-risk patients showed a
decreasing risk.63 The timing of HSCT has been studied using
Markov models in several retrospective studies.64-66 Delay of HSCT
in lower-risk MDS patients is associated with the best achievable
life expectancy, whereas conﬂicting ﬁndings were reported for
intermediate-1 risk (IPSS) patients. Superior survival was observed
when HSCT was delayed for intermediate-1 IPSS patients,65 whereas
another study64 showed better survival in intermediate-1 risk patients
when HSCT was performed at diagnosis. In patients with lower-risk
disease, HSCT may be best carried out when progression occurs to
intermediate-1 risk (by IPSS) or intermediate risk byWPSS.64 Several
poor-risk factors, including frequent RBC transfusions ($2 units per
month), life-threatening cytopenias (neutrophil counts,,0.33 109/L
or platelet counts,,303 109/L) and very-poor prognostic cytogenetic
markers might be identiﬁed both in lower-risk and in intermediate-risk
patients and justify HSCT early after diagnosis (Figure 1). In the
remainingpatients,HSCTmaybeproposed after a change inprognosis.
However, in a study of 374 patientswith refractory anemia (RA) and no
progression, survival was improved in patients transplanted ,1 year
from diagnosis.67 The panel agreed that deterioration of cytopenias,
which does not affect the IPSS-R classiﬁcation, should not necessarily
imply a recommendation to proceed to HSCT (recommendation level
D). If an increase of myeloblasts leads to a more advanced-risk group
by IPSS-R, the expert panel recommended proceeding to HSCT
(recommendation level C) (Figure 2). Patients become candidates for
HSCT if additional cytogenetic aberrations lead to more advanced-risk
classiﬁcation (recommendation level C).64
Poor-risk factors not included in IPSS-R. Transfusion de-
pendence has been recognized as a prognostic factor in the original
WPSS.41 The gain in life expectancy was 4 years when HSCT was
performed inMDS patients with intermediate risk according toWPSS,
in contrast to patients considered intermediate-1 risk according to
IPSS.64 The difference between the 2 risk classiﬁcations is mainly
based on the consideration of multilineage dysplasia and transfusion
dependency. These differences may not play a rolewhen using IPSS-R
because of the weighting of severe anemia (hemoglobin levels
,8 g/dL), which is usually associated with transfusion dependency.20
Progression of anemia, leading to heavy transfusion burden and lack
of response to erythropoietin-stimulating agent (ESA) treatment in
lower-risk patients should be considered an indication for HSCT.
Increase of transfusion frequency, and a cumulative number of
transfusions .20 units are frequently considered as an appropriate
time point for HSCT, but the expert panel did not reach consensus
about the exact timing. Presence and acquisition of poor-risk
mutations, such as TP53 mutations, may alter the prognosis at
diagnosis or later (for details, see “Risk factors”).
Failure of nontransplant strategies. Certain groups of lower-
risk MDS patients are likely to respond to speciﬁc therapy, including
ESAs (low erythropoietin [EPO] levels, low or absent transfusion
requirements),6,68 lenalidomide (presence of 5q2),5 andRAwith ringed
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sideroblasts/RCMD with ringed sideroblasts with speciﬁc spliceosome
mutations.69 Therefore, these patients are generally considered for
HSCT only after failure of these speciﬁc treatment options (Table 1;
Figure 1).Higher-risk patients often receive cytoreductive or epigenetic-
modifying treatment before considering HSCT and referral to a
transplant center for various reasons. The recommendations for the
selectionand timingofpatientswhohavebeen treatedwith ICTorHMA
will be discussed in this section, taking into account the response to
treatment at time of evaluation (complete/partial response, no response
or progression after response).
After failure of ICT. The majority of MDS patients, trans-
planted after ICT, were transplanted after primary or secondary failure
of ICT.70 The 5-year disease-free survival (DFS) of patients trans-
planted not in complete remission (CR) after ICT was only 18%.31
Patients with primary failure or relapse after ﬁrst-line ICT are
candidates for HSCT. Direct HSCT after failure of ﬁrst-line ICT is
recommended, if the BM blast percentage is,10% (recommendation
level D). Also, patients relapsing within 1 year after reaching CR or
showing resistance with higher percentages of marrow blasts are
candidates for HSCT, but the preparation for transplantation is less
clear.Additional studies are required in thesepatients (recommendation
level D). However, if relapse occurs after prolonged CR-1 (.1 year),
remission induction with ICT to induce CR-2 is recommended
(recommendation level C). Both standard and alternative donors are
recommended for those recipients (recommendation level C).
After failure of HMA treatment. Superior survival after treatment
with HMA may be predicted in patients with a HMA therapy-speciﬁc
risk score (zero points), based on absence of circulating blasts, presence
of good-risk cytogenetics and low transfusion requirements (,4 units
RBCsper 8weeks) (Table 1).71TET2orP53mutationswere associated
with higher response rates to azacitidine treatment, but this did not
translate into improved survival.72-74 Median survival after failure of
HMA therapy is usually ,6 months.75,76 Treatment after azacitidine
failure in a study of 277 patients resulted in a median survival of
19 months in 37 patients treated with HSCT. This outcome was
signiﬁcantly superior to that obtained with other treatments or best
supportive care only.76HMAfailure shouldbe considered an indication
for HSCT where feasible (recommendation level D).
Factors relevant for the selection of cytoreductive treatment
prior to transplant conditioning
Cytoreductive therapy to improve disease stage prior to the start
of conditioning for HSCT. Large retrospective multicenter studies
have demonstrated that the percentage of BM blasts at the time of
transplantation signiﬁcantly inﬂuences outcome after HSCT for
MDS.45,62,77 The retrospective nature of these studies usually leads
to signiﬁcant bias due to patient selection. The expert panel re-
commended upfront HSCT in higher-risk patients with ,10% BM
blasts (Figure 2).
Hypomethylating agents. The use of HMAs to prepare MDS
patients with an excess ofmarrowblasts for HSCT has been reported in
several retrospective studies.78,79 The available evidencedoes not allow
speciﬁc recommendations on the use of HMA for this purpose outside
of clinical trials or prospective registry studies.7,80,81 These studies need
to address several important questions, including which factors could
predict beneﬁt from HMA therapy prior to the transplant conditioning
and the optimal timing of HSCT. The expert panel did not reach
consensus to continue HMA therapy or to propose HSCT if patients
reached CR after HMA therapy. However, patients with stable disease
after 6 or more courses of HMA therapy are considered candidates for
HSCT (recommendation level D).
Intensive chemotherapy. ICT in patients with MDS is associ-
ated with considerable toxicity, leading to treatment-related mortality
(TRM)up to16%after intensive remission-induction chemotherapy.82,83
There was no evidence of a clear beneﬁt in posttransplantation outcome
associated with prior ICT for patients with MDS or AML after MDS.26
However, a prospective study84 showed a signiﬁcantly superior survival
in the donor group, in cases with intermediate- or poor-risk cytogenetic
criteria according to IPSS. A large retrospective study85 evaluated the
impact of cytogenetic risk groups on outcome after upfront HSCT and
HSCT in CR after ICT. The outcome of higher-risk MDS patients and
poor-risk cytogenetics was inferior when patients were transplanted
in CR, comparedwith comparable patients who received upfront HSCT.
Further studies that will randomize patients to ICT vs no ICT are needed
to appropriately address the beneﬁt of ICT. The expert panel re-
commended to transplant higher-risk MDS with poor-risk cytogenetic
characteristics in CR after ICT on investigational protocols only.
Usually, AML patients in CR received 1 or more consolidation
courses prior to HSCT,86 but ICT to consolidate CR in MDS patients
is less efﬁcient due to early relapses and prolonged hypoplasias.4
Informative analyses concerning this issue are lacking.The expert panel
advised to recommend that MDS patients who have entered CR after
ICT proceed to HSCT without further attempts to consolidate CR
(recommendation level D), but prospective studies are necessary to
evaluate the value of consolidation courses in MDS patients who have
entered CR after ICT.
The choice between HMA and ICT. A few retrospective
studies have addressed the question, which cytoreductive approach
prior to HSCT conditioning is associated with superior outcome.78,87
The Seattle group compared pretreatment with ICT and HMA.78 The
relapse rates after HSCT for the 2 cohorts were similar after adjustment
for several prognostic factors including cytogenetic risk groups,
supporting the growing evidence that HMA therapy prior to the
conditioning for HSCTmight be associated with less toxicity than ICT
and may allow for similar outcomes after HSCT. A French study
reported on 163 MDS patients87 who had received either ICT alone,
HMA alone, or HMA after ICT. The multivariate analyses revealed no
difference between the ICT andHMApretreated groups.87 A prospective
randomized trial comparing ICT vs HMA therapy before HSCT is now
accruing (www.clinicaltrials.gov, identiﬁer NCT01812252).
The expert panel recommended reducing tumor load in ﬁt higher-
riskMDS patients with.10%marrow blasts and normal cytogenetics
without a preference for ICTorHMA.However, in similar patientswith
complex karyotype or the approach is less clear (recommendation
level D). The panel agreed to propose HSCT in these cases and agreed
that cytoreductive therapymight beuseful, but the type of cytoreductive
therapy remained controversial.
Factors relevant for selecting the intensity of
preparatory regimens
The expert panel deﬁned the various preparatory intensities according
to the classiﬁcation used by EBMT88 and the CIBMTR89 with some
minor modiﬁcations (supplemental Data Section 4). Most studies in
patients with MDS report equivocal outcome after commonly used
myeloablative (MA) regimens.77,90-93 Many retrospective studies have
assessed the value of RI conditioning (RIC) compared with MA
regimens in patients with MDS.12,17,94,95 These studies showed
signiﬁcantly increased relapse rates after RIC when compared with
patients transplanted after MA regimens, but decreased NRM in the
RIC cohorts, resulting in a comparable overall survival of both groups.
Higher-risk patients with good performance status and no comorbidities
are candidates for MA regimens, whereas less ﬁt patients or patients
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with comorbidities should be considered for RIC schedules (recommen-
dation level C).
The MRD level of patients in remission before HSCT, may
inﬂuence the outcome after HSCT depending on the intensity of
conditioning. MRD was determined by FCM and cytogenetics in
219 patients in remission pre-HSCT, but 154 (54%) were MRD1,
whereas 65 (23%) were MRD2. The impact of MRD on outcome was
signiﬁcantly different between patients who received RI regimens and
patients who received a MA regimen. The impact of a positive marker
for MRD by cytogenetics was more detrimental after RIC than the
presence of such a marker among patients who received a MA
regimen.96 The expert panel recommended not to adopt pretreatment
decisions based on intensity of planned conditioning, but to focus on
posttransplant strategies, including chimerism and/or MRD monitor-
ing, to prevent relapse (see “Posttransplantation strategies”; recom-
mendation level D).
Posttransplantation strategies
Monitoring of mixed chimerism and residual disease. Several
techniques can be used to monitor chimerism before and after HSCT
to detect single nucleotide polymorphisms between donor and
recipients in whole BM and sorted subpopulations.97-99 Declining
donor chimerism or mixed chimerism early after HSCT are usually
considered signs of imminent relapse. Monitoring of chimerism in
sorted CD34 cells has been used as MRD monitoring after HSCT in
MDS.98 Molecular monitoring after HSCT has been performed
retrospectively in 36 MDS/myeloproliferative neoplasm patients.
Patients with detectable mutations (ASXL1, CBL, TET2, or NRAS)
after HSCT had a higher incidence of relapse than in patients with
undetectable mutations.100
Prevention and treatment of relapse after HSCT. Relapse
remains the leading cause of failure after HSCT,70,95 especially after
RIC.88,99 Treatment options for MDS relapse after HSCT consist of
palliative care, low-dose care, treatmentwithHMAor ICT, and cellular
immunotherapy, either donor lymphocyte infusions (DLIs) or second
HSCT. DLIs can be administered prophylactically (pDLI) at time of
persisting or declining mixed donor/recipient chimerism101 or in
recipients without signs of graft-versus-host disease (GVHD)102 or
therapeutically in cases of conﬁrmed relapse (DLI). DLI to treat
relapsedMDS after HSCT has moderate efﬁcacy with prolonged post-
DLI event-free survival ranging from 15% to 31%.101,103-105 The
combination of DLI and azacitidine to treat relapse after HSCT in 154
patientsMDS orAMLwithMDS-related changes showed a promising
2-year survival of 66%6 10% of the 28MDS patients with relapse.106
Cellular immunotherapy for treatment of 147 patients with MDS
relapse after HSCT was associated with superior survival, when
comparedwith cytoreductive therapy or supportive care only.107 Using
a different donor than the one used in the ﬁrst HSCT does not seem to
add further beneﬁt.108 Prophylactic DLI has shown promising results
with long-term event-free survival after starting pDLI up to 77%.102
Increasing doses of azacitidine to prevent relapse in patients at high risk
for relapse after HSCT have been tested in a phase 2 study109 with a
median event-free survival of 18 months. A recent study showed that
monthly courses of azacitidine after HSCT induced a cytotoxic CD8
T-cell response to several tumor antigens110 and an improved relapse-
free survival.111 The expert panel recommended in MDS patients with
mixed (,90% donor cells) or increasing recipient chimerism (.10%
recipient) after HSCT, rapid tapering of immunosuppression followed
by pDLI in case of absent GVHD (recommendation level C). The
expert panel could not recommend any speciﬁc intervention if MDS
relapsedclinicallywithin6monthsafterHSCT.Thepanel recommended
a type of immunemodulation in cases inwhich relapse occurred beyond
6 months after HSCT. However, more prospective studies are necessary
to identify the most appropriate approach forMDS relapsed after HSCT,
including studies combiningHMAsandDLIs (recommendation levelD).
Monitoring and prevention/treatment of iron overload.
Iron toxicity may be caused by frequent RBC transfusions, release of
toxic iron radicals by the transplant conditioning, causing cytotoxicity
and ineffective hematopoiesis, as well as by other less well-deﬁned
processes.112 Several noninvasive tests are available to assess iron
overload and iron toxicity (supplemental Data Section 5). The expert
panel could not recommend a speciﬁcmethod to evaluate iron overload
in the transplant setting. Ferritin levels may be predictive for survival,
but confounding variables may obscure the impact of ferritin levels in
determining the level of ironoverload.113Reductionof ironoverloadby
iron chelation prior to HSCT was associated with improved survival
and reduced NRM in a pediatric HSCT study.114 The expert panel
agreed that MDS patients with a transfusion history of .20 units of
RBCs, who are potential candidates for HSCT should receive appropriate
iron chelation therapy prior to conditioning for transplantation, similar to
several other guidelines7 (recommendation level D).
Ironoverload afterHSCTmaybe treatedbyphlebotomies or by iron
chelation (supplementalDataSection 5).115,116 The expert panel agreed
to recommend treatment of iron overload after HSCT in patients with
a high transfusion burden, but the choice between phlebotomies and
iron chelation remained open due to the lack of prospective studies
(recommendation level D).
Overall conclusions
HSCT is increasingly applied in the treatment of MDS after the
introduction of RIC regimens and the increased availability of well-
matched unrelated donors. Several new developments may inﬂuence
the outcome and application of HSCT. The recently introduced new
techniques may change the predictive models. These techniques may
allow better monitoring of minimal residual disease and improve both
nontransplant and transplant strategies. Several newclasses of drugs are
being tested in MDS patients. Positive outcome of these studies may
change the need for upfront and delayed HSCT in MDS. Currently,
the MDS working group of the ELN is developing an interactive
website (https://mds-europe.eu) supported by the MDS-Right Project
(funded by the EU Horizon 2020 project no. 634789), which will
support fast incorporation of new developments in the current HSCT
recommendations.
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